TASK DEFINITION: Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
PROBLEM: The company has since mid-March launched three coronavirus tests, including an antibody test crucial in identifying immunity among people and one that can deliver results within minutes, which was heralded as a game changer by President Donald Trump. Shares of the company were up 6% at $96.48 in morning trading. Despite the strong uptake in coronavirus testing, the cancellation of non-essential surgeries and restrictions on people's movement are expected to severely crimp sales of its medical devices and other lab tests, which contribute to more than half of total quarterly revenue. "(The second quarter) will likely be our toughest quarter in the year, especially for our core lab business, our cardio and neuro businesses," Chief Executive Officer Robert Ford said on a post-earnings call. The company suspended its full-year forecast due to the uncertainty caused by the health crisis and said it expects to provide an update in the second half of the year. Abbott projected a recovery in elective procedures and testing volumes globally from the third quarter and said it was seeing signs of stabilization in China and areas where the outbreak has begun to abate. "We're all hoping for a fast recovery here, but if it takes longer, we'll have strong demand for testing and that will continue to help buffer the impact," Ford said. Elective procedure declines were at the core of Johnson & Johnson's (JNJ.N) decision to cut 2020 forecasts on Tuesday, with recovery expected in the second half of the year. Abbott beat first-quarter earnings expectations as shelter-in-place restrictions imposed by U.S. states boosted demand for nutrition products for children such as PediaSure, lifting sales in the unit by 6.3% to $1.90 billion. Results were also boosted by a strong flu season before the outbreak that helped minimize testing declines and on softer-than-expected COVID-19 impact across businesses, said J.P. Morgan analyst Robbie Marcus. Sales in the diagnostics unit fell nearly 1% to $1.83 billion, while demand for its FreeStyle Libre diabetes monitoring device remained strong fueled by expanded insurance coverage in Japan. Sales of the device surged 60% to over $600 million. Excluding items, the company earned 65 cents per share, beating expectation of 58 cents. Net sales of $7.73 billion also topped estimates of $7.34 billion.

SOLUTION: Coronavirus test ramp-up to help Abbott weather 'toughest quarter'.

PROBLEM: The verdict in the lawsuit brought by the California woman, Eva Echeverria, marks the largest sum awarded in a series of talcum powder lawsuit verdicts against Johnson & Johnson in courts around the U.S. Echeverria alleged Johnson & Johnson failed to adequately warn consumers about talcum powder's potential cancer risks. She used the company's baby powder on a daily basis beginning in the 1950s until 2016 and was diagnosed with ovarian cancer in 2007, according to court papers. Echeverria developed ovarian cancer as a "proximate result of the unreasonably dangerous and defective nature of talcum powder," she said in her lawsuit. Echeverria's attorney, Mark Robinson, said his client is undergoing cancer treatment while hospitalized and told him she hoped the verdict would lead Johnson & Johnson to put additional warnings on its products. "Mrs. Echeverria is dying from this ovarian cancer and she said to me all she wanted to do was to help the other women throughout the whole country who have ovarian cancer for using Johnson & Johnson for 20 and 30 years," Robinson said. "She really didn't want sympathy," he added. "She just wanted to get a message out to help these other women." The jury's award included $68 million in compensatory damages and $340 million in punitive damages, Robinson said. The evidence in the case included internal documents from several decades that "showed the jury that Johnson & Johnson knew about the risks of talc and ovarian cancer," Robinson said. "Johnson & Johnson had many warning bells over a 30 year period but failed to warn the women who were buying its product," he said. Johnson & Johnson spokeswoman Carol Goodrich said in a statement that the company will appeal the jury's decision. She says while the company sympathizes with women suffering from ovarian cancer that scientific evidence supports the safety of Johnson's baby powder. The verdict came after a St. Louis, Missouri jury in May awarded $110.5 million to a Virginia woman who was diagnosed with ovarian cancer in 2012. She had blamed her illness on her use of the company's talcum powder-containing products for more than 40 years. Besides that case, three other trials in St. Louis had similar outcomes last year with juries awarding damages of $72 million, $70.1 million and $55 million, for a combined total of $307.6 million. Another St. Louis jury in March rejected the claims of a Tennessee woman with ovarian and uterine cancer who blamed talcum powder for her cancers. Two similar cases in New Jersey were thrown out by a judge who said the plaintiffs' lawyers did not presented reliable evidence linking talc to ovarian cancer. More than 1,000 other people have filed similar lawsuits. Some who won their lawsuits won much lower amounts, illustrating how juries have wide latitude in awarding monetary damages. Johnson & Johnson is preparing to defend itself and its baby powder at upcoming trials in the U.S., Goodrich said. ___ Associated Press writer Amanda Lee Myers contributed to this report. ___ Follow Michael Balsamo on Twitter at http://twitter.com/MikeBalsamo1 .

SOLUTION: Record $417M award in lawsuit linking baby powder to cancer.

PROBLEM: According to statistics through Saturday, there were 3,395 cases included 63 new cases reported the prior week. To underscore the outbreak, the Panama City News Herald reported the state totaled 1,175 reported cases of hepatitis A in the five previous years combined with 548 of those cases in 2018, according to state Department of Health data. Hepatitis A can cause liver damage and is spread through such things as fecal matter. That can include transmission by people not properly washing their hands after going to the bathroom and contaminating food or drinks. Health officials urge people to get vaccinated against the disease. As of Saturday, Pasco County had the most cases in the state in 2019, with 414.

SOLUTION:
Nearly 3,400 Hepatitis A cases reported in Florida in 2019.